{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:24Z","timestamp":1787021244327,"version":"build-2736575974"},"reference-count":28,"publisher":"The Endocrine Society","issue":"4","funder":[{"name":"Jody Ginsberg Scholarship, Division of Endocrinology, University of Alberta"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Clinical islet transplantation (CIT) is an innovative strategy to treat highly selected individuals with type 1 diabetes mellitus (T1DM). Lymphodepletion with alemtuzumab or thymoglobulin is often used for induction therapy in CIT. Alemtuzumab was recently licensed as a treatment of relapsing remitting multiple sclerosis (RRMS). In RRMS, autoimmune thyroid disease (AITD) has developed in up to 40% of individuals treated with alemtuzumab. The appearance of AITD after CIT is not well described. We herein explore factors associated with AITD developing after CIT and any relationship with exposure to lymphodepleting antibodies (alemtuzumab or thymoglobulin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Description<\/jats:title>\n                    <jats:p>Five cases of AITD developing after CIT for T1DM are described. All were female. Four cases had received alemtuzumab (20 to 40 mg) prior to at least one islet infusion, and one received thymoglobulin induction. The presentation with AITD was 18 to 135 months after first transplant and 11 to 18 months after withdrawal of all maintenance immunosuppression (IS). Four cases presented with clinical and biochemical evidence of hyperthyroidism from Graves disease. One case presented with biochemical evidence of hypothyroidism and positive TSH receptor antibodies. All were treated with conventional therapies for AITD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite routine use of alemtuzumab, clinical presentations of AITD seem to be uncommon in patients with CIT receiving IS. However, AITD can develop after withdrawal of IS, highlighting the need for careful thyroid surveillance in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2018-01652","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T13:05:36Z","timestamp":1541423136000},"page":"1141-1147","source":"Crossref","is-referenced-by-count":6,"title":["Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9064-1984","authenticated-orcid":false,"given":"Alanna","family":"Dunn","sequence":"first","affiliation":[{"name":"Division of Endocrinology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M James","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Department of Surgery, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"Senior","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"issue":"7","key":"2020071621523841600_B1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2337\/dc15-1988","article-title":"Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia","volume":"39","author":"Hering","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"2020071621523841600_B2","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2337\/diabetes.54.7.2060","article-title":"Five-year follow-up after clinical islet transplantation","volume":"54","author":"Ryan","year":"2005","journal-title":"Diabetes"},{"issue":"7","key":"2020071621523841600_B3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ni.2610","article-title":"T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10","volume":"14","author":"Bandala-Sanchez","year":"2013","journal-title":"Nat Immunol"},{"issue":"11","key":"2020071621523841600_B4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1089\/thy.2013.0241","article-title":"Thyroid dysfunction as an unintended side effect of anticancer drugs","volume":"23","author":"Torino","year":"2013","journal-title":"Thyroid"},{"issue":"8","key":"2020071621523841600_B5","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.bbmt.2018.03.029","article-title":"High incidence of autoimmune disease after hematopoietic stem cell transplantation for chronic granulomatous disease","volume":"24","author":"Yanir","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9191","key":"2020071621523841600_B6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","article-title":"Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis","volume":"354","author":"Coles","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"2020071621523841600_B7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"2020071621523841600_B8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"2020071621523841600_B9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nrg1944","article-title":"Genetics of autoimmune diseases: disorders of immune homeostasis","volume":"7","author":"Gregersen","year":"2006","journal-title":"Nat Rev Genet"},{"issue":"2","key":"2020071621523841600_B10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s13340-018-0352-4","article-title":"Diabetes mellitus and thyroid diseases","volume":"9","author":"Nishi","year":"2018","journal-title":"Diabetol Int"},{"issue":"2","key":"2020071621523841600_B11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1464-5491.2007.02048.x","article-title":"Prevalence of autoimmune diseases in islet transplant candidates with severe hypoglycaemia and glycaemic lability: previously undiagnosed coeliac and autoimmune thyroid disease is identified by screening","volume":"24","author":"Walter","year":"2007","journal-title":"Diabet Med"},{"issue":"10","key":"2020071621523841600_B12","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/j.1600-6143.2007.01923.x","article-title":"High risk of sensitization after failed islet transplantation","volume":"7","author":"Campbell","year":"2007","journal-title":"Am J Transplant"},{"issue":"1","key":"2020071621523841600_B13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-6143.2010.03348.x","article-title":"Three cases of alopecia following clinical islet transplantation","volume":"11","author":"Zuk","year":"2011","journal-title":"Am J Transplant"},{"issue":"2","key":"2020071621523841600_B14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2009.03.012","article-title":"TSH receptor autoantibodies","volume":"9","author":"Michalek","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"11","key":"2020071621523841600_B15","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1007\/s00415-018-8822-y","article-title":"Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations","volume":"265","author":"Devonshire","year":"2018","journal-title":"J Neurol"},{"issue":"10","key":"2020071621523841600_B16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc08-2339","article-title":"Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic Islet cell recipients with pretransplant TPO autoantibodies","volume":"32","author":"Gillard","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"2020071621523841600_B17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2020071621523841600_B18","doi-asserted-by":"crossref","unstructured":"De Mercanti S , RollaS, CucciA, BardinaV, CoccoE, VladicA, Soldo-ButkovicS, HabekM, AdamecI, HorakovaD, AnnovazziP, NovelliF, DurelliL, ClericoM. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm. 2016;3(1):e194.","DOI":"10.1212\/NXI.0000000000000273"},{"issue":"12","key":"2020071621523841600_B19","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.4049\/jimmunol.1301926","article-title":"Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis","volume":"191","author":"Zhang","year":"2013","journal-title":"J Immunol"},{"issue":"7","key":"2020071621523841600_B20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/TP.0b013e31820c85dc","article-title":"Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy","volume":"91","author":"Hester","year":"2011","journal-title":"Transplantation"},{"issue":"8","key":"2020071621523841600_B21","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20070663","article-title":"Phenotypic and functional features of human Th17 cells","volume":"204","author":"Annunziato","year":"2007","journal-title":"J Exp Med"},{"key":"2020071621523841600_B22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.lfs.2017.11.026","article-title":"Autoimmune thyroid diseases and Th17\/Treg lymphocytes","volume":"192","author":"Shao","year":"2018","journal-title":"Life Sci"},{"issue":"1","key":"2020071621523841600_B23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13044-018-0046-9","article-title":"Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases","volume":"11","author":"Rydzewska","year":"2018","journal-title":"Thyroid Res"},{"issue":"1","key":"2020071621523841600_B24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imm.12178","article-title":"Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro","volume":"141","author":"Havari","year":"2014","journal-title":"Immunology"},{"issue":"3","key":"2020071621523841600_B25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"50","key":"2020071621523841600_B26","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2020071621523841600_B27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"2020071621523841600_B28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/4\/1141\/27979740\/jc.2018-01652.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/4\/1141\/27979740\/jc.2018-01652.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T05:24:33Z","timestamp":1662355473000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/4\/1141\/5155463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-01652","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,11,5]]}}}